Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.32 |
| ▸ | HTR2A | P28223 | 8/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550680 | 1.00 | HTR2C (0.32) | HTR2CHTR2AGRM2HDAC3HDAC1 | |
| SCHEMBL26782296 | 0.91 | HTR2C (0.36) | HTR2CHTR2AGRM2HDAC3HDAC1 | |
| SCHEMBL25321710 | 0.78 | TNF (0.39) | GRM2HDAC3HDAC1HDAC6 | |
| SCHEMBL25898525 | 0.74 | HTR2C (0.40) | HTR2CHTR2AGRM2HDAC3HDAC1 | |
| SCHEMBL25323865 | 0.73 | GRM2 (0.34) | GRM2 | |
| SCHEMBL25899446 | 0.72 | BRD4 (0.38) | — | |
| SCHEMBL25322354 | 0.70 | TNF (0.32) | — | |
| SCHEMBL30550743 | 0.70 | TNF (0.32) | — | |
| SCHEMBL26782295 | 0.70 | TNF (0.32) | — | |
| SCHEMBL25324896 | 0.68 | PSMB1 (0.41) | HDAC3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | HTR2C 1861/4885HTR2A 2837/4885GRM2 4803/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | HTR2C 1861/4885HTR2A 2837/4885GRM2 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.